ARAlbert Massó van Roessel

Albert Massó van Roessel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Albert Massó van Roessel has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Outcomes and Valve Performance of Intra‐Annular Self‐Expanding Transcatheter Aortic Valve in Valve‐in‐Valve Procedures: Insights From the NAViV Registry

    by Jorge Chavez, Gabriela Tirado‐Conte, Yusuke Kobari, Lluis Asmarats, Alberto Berenguer, Alba Abril Molina, Jose Ramón Lopez‐Minguez, Ander Regueiro, Antonio Gomez Menchero, Livia Georghe, et al.

    Background: Most evidence for transcatheter aortic valve replacement (TAVR) for valve‐in‐valve procedures comes from balloon‐expandable and supra‐annular self‐expanding valves. However, data on intra‐annular self‐expanding valves remain limited. The objectives of this registry were to evaluate the short‐ and midterm outcomes of ViV‐TAVR using the intra‐annular self‐expanding valve Navitor platform in a real‐world setting. Methods: The NAViV (Navitor Valve‐in‐Valve) registry is a retrospective, multicenter study that included 200 patients who underwent valve‐in‐valve TAVR with the Portico/Navitor systems. The primary end point was 30‐day device success. Secondary outcomes included intraprocedural technical success, early safety, and all‐cause death and major adverse events at 2 years. Results: The cohort had a high‐risk profile and a high prevalence of small surgical bioprostheses (internal diameter ≤21 mm in 86% of the patients). Technical success was achieved in 96%, with an in‐hospital mortality rate of 2% and early safety at 30 days of 84%. Mean residual gradients after TAVR were low (14 [interquartile range, 10–20] mm Hg), and residual significant aortic regurgitation was rare (1%). Device success was 73.5%, with high residual gradients (≥20 mm Hg) being the main reason for device failure. Two‐year survival and major adverse events were 85.6% and 69.8%, respectively; with low residual gradients and baseline significant AR being independently associated with higher survival. Conclusions: Valve‐in‐valve TAVR using the Portico/Navitor intra‐annular self‐expanding valve demonstrates a favorable procedural safety profile, sustained valve performance, and encouraging midterm survival in intermediate‐ and high‐risk populations. Larger and comparative studies are warranted to confirm these findings.

  • Outcome of Insertable Cardiac Monitors in Symptomatic Patients with Brugada Syndrome at Low Risk of Sudden Cardiac Death

    by Julián Palacios-Rubio, Albert Massó-Van Roessel, Victoria Galizia-Brito, Carmen Expósito-Pineda, Carlos Grande-Morales

    Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.